Dyne Therapeutics, INC Form 4 insider transactions

Dyne Therapeutics CEO John Cox sold 4,061 shares of common stock on March 5, 2025, to satisfy tax withholding obligations related to vesting restricted stock units.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 917 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 1,094 shares of common stock to cover tax obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 2,488 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Director Jason P. Rhodes reports acquisition of Dyne Therapeutics shares through indirect ownership.

Dyne Therapeutics' Chief Scientific Officer, Oxana Beskrovnaya, sold shares to cover tax obligations related to vested restricted stock units.

A Dyne Therapeutics executive sold shares to cover tax obligations related to vesting restricted stock units.

A Dyne Therapeutics insider, Dirk Kersten, sold a significant number of shares in multiple transactions at weighted average prices between $29.00 and $29.66.

Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, acquired 37,800 shares of common stock through restricted stock units and 60,300 stock options on December 4, 2024.

Dyne Therapeutics director Dirk Kersten sold a total of 138,845 shares of common stock in multiple transactions over two days.

Richard William Scalzo, SVP, Head of Finance & Admin at Dyne Therapeutics, acquired shares and stock options on December 4, 2024.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, acquired 48,000 shares of common stock through restricted stock units and 76,600 stock options on December 4, 2024.

Dyne Therapeutics CEO, John Cox, acquired 145,300 shares of common stock through restricted stock units and 232,100 stock options on December 4, 2024.

Dyne Therapeutics' Chief Scientific Officer, Oxana Beskrovnaya, acquired shares and stock options, increasing her beneficial ownership in the company.

Dyne Therapeutics director Dirk Kersten sold a total of 110,933 shares of common stock in multiple transactions over two days, December 2nd and 3rd, 2024.

Dyne Therapeutics director Carlo Incerti exercised stock options and sold the resulting shares on November 18, 2024.

Director Jason P. Rhodes of Dyne Therapeutics sold a total of 782 shares of common stock across multiple transactions on November 14, 2024, at an average price of $33.1.

Richard Scalzo, SVP at Dyne Therapeutics, sold 2,735 shares to cover tax obligations related to vesting restricted stock units.

Dyne Therapeutics' Chief Scientific Officer, Oxana Beskrovnaya, sold 2,856 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Dyne Therapeutics director, Dirk Kersten, sold a total of 19,732 shares of common stock in multiple transactions over two days.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock on October 16 and 17, 2024, through entities associated with Forbion Capital Fund IV.

Director Dirk Kersten reports the sale of Dyne Therapeutics shares under a pre-arranged trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through entities he is associated with, under a pre-arranged trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock made under a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports selling shares of Dyne Therapeutics (DYN) on September 18 and 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, sold shares of common stock to cover tax obligations related to vesting restricted stock units and under a pre-arranged 10b5-1 trading plan.